INDIA'S pharmaceutical industry is looking to partner with Malaysian companies to expand manufacturing of off-patented medicines, said a visiting Indian government official.
Atlanta-based Altea Therapeutics has inked a $46 million deal with Eli Lilly and Amylin Pharmaceuticals to develop and commercialize a daily transdermal patch delivering sustained levels of Byetta (exenatide).
Sigma-Aldrich announced an agreement to supply high quality services and oligonucleotides to Gene Oracle, an innovative gene synthesis company. Under the terms of the agreement, Sigma-Aldrich will be the exclusive supplier of custom oligonucleotides for Gene Oracle, and the two companies will engage in co-marketing efforts to promote the GeneIOS system and their expert gene synthesis services.
Genzyme has scooped up key worldwide rights to the leukemia drug Campath–which is being studied as a treatment for MS–and two cancer therapies from its development partner Bayer HealthCare in a deal with a potential $2.8 billion payout.
The “Pharmaceutical Leadership Summit 2009” to be held at under the theme Destination India – Challenges & Oppurtunities, to be held in Hotel Renaissance Mumbai Hotel and Convention Centre in Grand Ball Room # 2 & 3B, Near Chinmayanand Ashram, Powai, Mumbai 400 087 on Friday, 3rd April 2009 .
NovaBay Pharmaceuticals, Inc, mid-stage biopharmaceutical company developing first-in-class anti-infective products for the treatment and prevention of a wide range of infections without causing resistance, has entered into an agreement with Galderma SA to develop and commercialize NovaBay's novel proprietary Aganocide compounds.
Eli Lilly has struck a drug discovery and research pact with India's Cadila Healthcare, the latest in a string of innovative R&D deals in the subcontinent.
Shire plc, the global specialty biopharmaceutical company, announced a co-promotion agreement with GlaxoSmithKline plc for Vyvanse (lisdexamfetamine dimesylate) capsules CII with the aim of improving recognition and treatment of ADHD in adults.
Piramal Healthcare Ltd plans to shut its manufacturing unit in Huddersfield in the United Kingdom, a company official said.
The contract research organisations in the country have called for better regulatory environment including permission for phase-1 clinical trials to attract more foreign companies to the land as the country has huge potential to improve its share in the global market.
Institute of Clinical Research (India), ICRI in collaboration with Cranfield University, UK has called for applications for its two year full time course, MSc in Clinical Research. The course will start on August 3 at all its campuses in Bangalore, Mumbai, Delhi, Ahmedabad & Hyderabad.
Nitec Pharma AG, a Switzerland-based pharmaceutical company focused on the development and commercialization of medicines and treatment solutions for chronic inflammation and pain-related diseases, has signed an agreement with Mundipharma International Corporation Limited, a UK-based company engaged in the research, development, manufacturing, and marketing of pharmaceuticals, under which Mundipharma has obtained an exclusive license for the distribution of Lodotra(TM) in Europe, excluding Germany and Austria which are licensed to Merck KGaA.
ReSearch Pharmaceutical Services (RPS), a Delaware-based provider of clinical solutions to the bio-pharmaceutical industry, has acquired medical research organisation Paramax International for $1 million (£700,000) in cash.
Indian drug makers are in much demand and Zydus Cadilla's research deal with global giant Eli Lilly is just one example. The deal is to partner for research of cardiovascular drugs with potential payments of up to $300 million in the long term for the Indian firm.
Janet Woodcock, director of the Center for Drug Evaluation and Research for the US Food and Drug Administration, spoke at the Drug, Chemical, and Associated Technologies Association (DCAT) annual dinner earlier this month, emphasizing the need of regulators and industry to meet the challenge of securing an increasingly complex global pharmaceutical supply chain. Her words were very well taken and show the recognition not only by FDA and other regulatory authorities, but also of pharmaceutical manufacturers and their suppliers, that the elongation of the global supply chain brings with it new responsibilities and ways of doing business.
The Russian pharmaceutical market is forecasted to grow at a CAGR of 14% by 2012 in the backdrop of rising population of elders and government’s initiatives to reform healthcare system.
Indian pharmaceutical companies with a presence in the sterile injectables space are expanding capacities to cater to growing demand in this segment. Bangalore-based Strides Arcolab, Elder Pharmaceuticals are some of the companies that have laid out plans for expansion of existing units and building new units to meet growing demand.
While the recent consolidation in pharma industry is an outcome of the challenges faced by the global pharma companies over the last few years, this spells good news for Indian pharmaceutical contract manufacturers such as Piramal Healthcare, Jubilant Organosys, Divis' Labs and Dishman Pharma.
Gone are the days when doctors, nurses, pharmacologists and other professionals in the medical field were found just in hospitals or labs.
GlaxoSmithKline and Sanofi-Aventis are reported to be in separate talks to buy a majority stake in Indian biotechnology firm that pioneered indigenous recombinant vaccines, Shantha Biotech.